Mutational profile of primary dermal melanoma: A case series

Abstract

how to use them (n ¼ 13) felt that they would be able to find someone to show them how. Sixty-eight percent of patients had camera phones, usually take them to doctor's appointments, and know how to use the camera function. Eighty-six percent had camera phones and either knew how to use them or could get someone to show them.Men (n ¼ 64) had a slightly higher probability than women (n ¼ 36) of having camera phones, bringing them to doctor's appointments, and knowing how to use them. Differences were greater when stratifying by age. More than 96% (96.4%) of respondents \70 years of age had camera phones, compared with 73.3% of patients $70 years of age. Only 46.7% of those $70 years of age had camera phones they take to the doctor and know how to use, compared with 85.5% of those \70 years of age. However, 73.3% of those $70 years of age had camera phones and either knew how to use them or could have someone help them; 96.4% of patients \70 years of age fell into this category. Most patients with camera phones were willing to take pictures (96.5% overall). One hundred percent of those \70 years of age were willing to take pictures, but only 90.9% of those $70 years of age who had camera phones were willing to take pictures.We feel that standardized, clinic-taken photographs at the time a biopsy specimen is obtained is the criterion standard for site identification. The increasing quality and ubiquity of camera phones, however, make them a viable alternative. We envision two scenarios for their use: (1) the physician obtaining the biopsy specimen asks the patient to photograph the site at the time the specimen is obtained or at the time of result notification, or (2) the treating surgeon's office asks the patient to photograph the site when treatment appointment is made. Our results show that patients are largely able and willing to comply with this request, although our patient demographics are likely not representative of those of many surgeons, particularly those practicing in urban centers. Increasing age is a possible predictor of those who are unable to participate. As the technology becomes more ubiquitous, a higher percentage of the population will likely be able to do so.

A case report of cutaneous melanocytoma with CRTC1‐TRIM11 fusion: Is CMCT distinct from clear cell sarcoma of soft tissue?

“…They hypothesized that cutaneous melanocytoma is a cutaneous form of CCS with a new fusion transcript based on their “malignant” case. However, we think “cutaneous melanocytoma” should be currently reserved for several reasons: (i) Their report of a “malignant” case lacked histological evidence of metastasis; (ii) Histology, such as uniform nests and fascicles of pale spindled or epithelioid cells, is not specific for dermal CCS, but instead overlaps with dermal MM and PDMT, in addition to CMCT . Therefore, the diagnosis of cutaneous/dermal CCS is better confined to cases with molecular confirmation of EWSR1‐ATF1/ CREB1, as has been done in previous studies dealing with such CCSs; (iii) Although the molecular function of CRTC1‐TRM11 fusion transcript is still unknown, TRIM11 protein is reported to interact with PAX6 and play a role in forming organs such as the brain and eyes .…”

Dermal melanocytic tumor with CRTC1‐TRIM11 fusion: Report of two additional cases with review of the literature of an emerging entity

“…The detection of CRTC1‐TRIM11 fusion and the lack of characteristic mutations (eg. BRAF, NRAS ) seen in conventional melanomas would support the diagnosis of CMTCT 31‐34 . It is conceivable that at least some cases reported as PDM are in fact CMTCT that may explain its more indolent behavior 1 .…”

“…Primary dermal melanoma (PDM) is typically described as a dermal lobular or multilobular tumor with spindle, epithelioid, or rhabdoid cells arranged in sheets or nests 29,30 . It behaves in a relative indolent fashion comparing to ordinary melanomas of similar thickness 31 . The detection of CRTC1‐TRIM11 fusion and the lack of characteristic mutations (eg.…”

Cutaneous Melanocytic Tumor with CRTC1::TRIM11 Fusion: Review of the Literature of a Potentially Novel Entity

“…Since a subset of PDMs behave in a low grade fashion compared to similar thickness conventional melanomas, it is plausible that some of them may represent CMTCT. [ 1 ] The detection of CRTC1::TRIM11 fusion and/or the lack of characteristic mutations and cytogenetic abnormalities of PDM could aid in the distinction between the two entities [ 4 , 31 , 32 , 33 ]. To exclude a metastatic or regressing melanoma, an extensive histopathologic and clinical work-up are necessary.…”